Lupin inks licensing pact with Alvion to market drugs in Southeast Asia

Lupin yesterday said it has inked a licensing pact with Alvion Pharma to commercialise medicines for cardiometabolic diseases in Southeast Asia.

The company said it is committed to provide affordable treatment options to healthcare providers and patients.

By commercialising cardiometabolic drugs in Southeast Asia, Lupin will play a significant role in improving the quality of healthcare and access to medicines, it added.

“Forming a long-term collaboration with Alvion to launch a range of therapies will allow Lupin to expand its footprint across Southeast Asia with quality cost effective alternatives for patients and the healthcare system,” Gabriel Georgy, Regional Head Southeast Asia, Lupin, said in a statement.

Both companies have a solid track record of developing and launching products and this agreement will further cement Lupin as a formidable pharmace company in the region, he added.

“Being a leader in value-added medicines, Alvion shall support Lupin’s activities aiming to position both companies at the forefront for both molecules,” John Bouros, CEO, Alvion, said.